Table 3.
Echocardiographic parameters in the mice with established cardiac dysfunction treated with B38-CAP for 2 weeks.
| Sham + vehicle | Sham + vehicle | TAC + vehicle | TAC + vehicle | TAC + B38-CAP | TAC + B38-CAP | |
|---|---|---|---|---|---|---|
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| N | 5 | 5 | 6 | 6 | 6 | 6 |
| Age (weeks) | 15 | 17 | 15 | 17 | 15 | 17 |
| BW (g) | 23.14 ± 1.24 | 25.82 ± 1.03 | 23.12 ± 0.87 | 25.92 ± 0.74 | 23.55 ±± 0.83 | 24.30 ± 1.16 |
| HR (bpm) | 594 ± 49 | 631 ± 68 | 551 ± 51 | 559 ± 49 | 570 ± 65 | 644 ± 61 |
| FS (%) | 51.78 ± 4.09 | 51.91 ± 1.56 | 29.49 ± 2.79*** | 27.20 ± 1.43 | 29.06 ± 2.36*** | 36.38 ± 2.03### †† |
| EF (%) | 76.70 ± 3.70 | 83.89 ± 1.27 | 57.44 ± 4.5*** | 53.56 ± 2.28 | 56.70 ± 3.54*** | 67.03 ± 2.86### †† |
| LVESD (mm) | 1.54 ± 0.15 | 1.54 ± 0.13 | 2.43 ± 0.38*** | 2.75 ± 0.14 | 2.49 ± 0.23*** | 2.15 ± 0.17## † |
| LVEDD (mm) | 3.20 ± 0.08 | 3.21 ± 0.22 | 3.44 ± 0.45 | 3.77 ± 0.17 | 3.51 ± 0.34 | 3.38 ± 0.24 |
| IVSD (mm) | 0.74 ± 0.04 | 0.79 ± 0.03 | 1.05 ± 0.17* | 1.04 ± 0.05 | 1.09 ± 0.05*** | 0.99 ± 0.07† |
| PWD (mm) | 0.78 ± 0.06 | 0.89 ± 0.13 | 1.11 ± 0.12*** | 0.99 ± 0.05 | 1.03 ± 0.06*** | 1.08 ± 0.09 |
Results are presented as mean ± SEM. One-way ANOVA plus Sidak’s multiple-comparisons test was used to detect significance.
BW body weight, FS left ventricular fractional shortening, EF left ventricular ejection fraction, HR heart rate, IVSD end-diastolic interventricular septal wall thickness, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, PWD left ventricular end-diastolic posterior wall.
*P < 0.05 vs. sham + vehicle before treatment; **P < 0.001 vs. sham + vehicle before treatment; ***P < 0.0001 vs. sham + vehicle before treatment; #P < 0.05 vs. TAC + vehicle after treatment; ##P < 0.001 vs. TAC + vehicle after treatment; ###P < 0.0001 vs. TAC + vehicle after treatment. Two-tailed paired t-test was used to detect significance. †P < 0.05 vs. TAC + B38-CAP before treatment; ††P < 0.001 vs. TAC + B38-CAP before treatment.